Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of etanercept and infliximab

Seminars in Arthritis and Rheumatism

Volumn 34, Issue 5 SUPPL., 2005, Pages 34-38

  Wallis, Robert S ^a,b,c   Ehlers, Stefan ^d  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b Pharmaceutical Product Development   (United States)

^c PPD   (United States)

^d RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; ETANERCEPT; HYBRID PROTEIN; INFLIXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

APOPTOSIS; BIOAVAILABILITY; BIOLOGY; CELL DEATH; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONFERENCE PAPER; CROHN DISEASE; CYTOLYSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; GRANULOMA; GRANULOMATOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; IN VIVO STUDY; INFECTION; INFECTION RISK; LUNG TUBERCULOSIS; MONOCYTE; MYCOBACTERIOSIS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TARGET CELL; TUBERCULOSIS;

EID: 17044409651     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2005.01.009     Document Type: Conference Paper

References (36)

1. M. Grell, E. Douni, H. Wajant, M. Lohden, M. Clauss, B. Maxeiner The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor Cell 83 5 1995 793 802
2. B. Scallon, A. Cai, N. Solowski, A. Rosenberg, X.Y. Song, D. Shealy Binding and functional comparisons of two types of tumor necrosis factor antagonists J Pharmacol Exp Ther 301 2 2002 418 426
3. F.J. Baert, G.R. D'Haens, M. Peeters, M.I. Hiele, T.F. Schaible, D. Shealy Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis Gastroenterology 116 1 1999 22 28
4. R.N. Serio Infliximab treatment of sarcoidosis Ann Pharmacother 37 4 2003 577 581
5. P. Lamprecht, J. Voswinkel, T. Lilienthal, B. Nolle, M. Heller, W.L. Gross Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis Rheumatology (Oxford) 41 11 2002 1303 1307
6. J.P. Utz, A.H. Limper, S. Kalra, U. Specks, J.P. Scott, Z. Vuk-Pavlovic Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis Chest 124 1 2003 177 185
7. W.J. Sandborn, S.B. Hanauer, S. Katz, M. Safdi, D.G. Wolf, R.D. Baerg Etanercept for active Crohn's disease a randomized, double-blind, placebo-controlled trial Gastroenterology 121 5 2001 1088 1094
8. M.H. Weisman What are the risks of biologic therapy in rheumatoid arthritis? An update on safety J Rheumatol 65 Suppl 2002 33 38
9. B.M. Saunders, A.M. Cooper Restraining mycobacteria role of granulomas in mycobacterial infections Immunol Cell Biol 78 4 2000 334 341
10. D.R. Roach, A.G. Bean, C. Demangel, M.P. France, H. Briscoe, W.J. Britton TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection J Immunol 168 9 2002 4620 4627
11. D.H. Canaday, R.J. Wilkinson, Q. Li, C.V. Harding, R.F. Silver, W.H. Boom CD4(+) and CD8(+) T cells kill intracellular Mycobacterium tuberculosis by a perforin and Fas/Fas ligand-independent mechanism J Immunol 167 5 2001 2734 2742
12. S. Stenger, D.A. Hanson, R. Teitelbaum, P. Dewan, K.R. Niazi, C.J. Froelich An antimicrobial activity of cytolytic T cells mediated by granulysin Science 282 5386 1998 121 125
13. J.L. Flynn, M.M. Goldstein, J. Chan, K.J. Triebold, K. Pfeffer, C.J. Lowenstein Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice Immunity 2 6 1995 561 572
14. E.A. Havell Evidence that tumor necrosis factor has an important role in antibacterial resistance J Immunol 143 9 1989 2894 2899
15. R. Allendoerfer, G.S. Deepe Jr. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms J Immunol 160 12 1998 6072 6082
16. S. Ehlers, S. Kutsch, E.M. Ehlers, J. Benini, K. Pfeffer Lethal granuloma disintegration in mycobacteria-infected TNFRp55-/- mice is dependent on T cells and IL-12 J Immunol 165 1 2000 483 492
17. S. Ehlers, J. Benini, S. Kutsch, R. Endres, E.T. Rietschel, K. Pfeffer Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium Infect Immunol 67 7 1999 3571 3579
18. V. Kindler, A.P. Sappino, G.E. Grau, P.F. Piguet, P. Vassalli The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection Cell 56 5 1989 731 740
19. C.A. Scanga, V.P. Mohan, H. Joseph, K. Yu, J. Chan, J.L. Flynn Reactivation of latent tuberculosis variations on the Cornell murine model Infect Immunol 67 9 1999 4531 4538
20. V.P. Mohan, C.A. Scanga, K. Yu, H.M. Scott, K.E. Tanaka, E. Tsang Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis possible role for limiting pathology Infect Immunol 69 3 2001 1847 1855
21. R. Fleischmann Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis Expert Opin Drug Saf 2 4 2003 347 365
22. R. Fleischmann, I. Iqbal, P. Nandeshwar, A. Quiceno Safety and efficacy of disease-modifying anti-rheumatic agents focus on the benefits and risks of etanercept Drug Saf 25 3 2002 173 197
23. M.A. Gardam, E.C. Keystone, R. Menzies, S. Manners, E. Skamene, R. Long Anti-tumour necrosis factor agents and tuberculosis risk mechanisms of action and clinical management Lancet Infect Dis 3 3 2003 148 155
24. R.S. Wallis, M.S. Broder, J.Y. Wong, J.Y. Hanson, D.O. Beenhouwer Granulomatous infectious diseases associated with TNF antagonists Clin Infect Dis 38 9 2004 1261 1265
25. R.S. Wallis, M. Broder, J. Wong, Beenhouwer Granulomatous infections associated with TNF antagonists correction ?? Clin Infect Dis 39 8 2004 1254 1255
26. T.M. Daniel, S.M. Debanne Estimation of the annual risk of tuberculosis infection for white men in the United States J Infect Dis 175 6 1997 1535 1537
27. H. Wajant, K. Pfizenmaier, P. Scheurich Tumor necrosis factor signaling Cell Death Differ 10 1 2003 45 65
28. M.L. Olleros, R. Guler, N. Corazza, D. Vesin, H.P. Eugster, G. Marchal Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-alpha J Immunol 168 7 2002 3394 3401
29. J.J. Peschon, D.S. Torrance, K.L. Stocking, M.B. Glaccum, C. Otten, C.R. Willis TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation J Immunol 160 2 1998 943 952
30. G. Kassiotis, G. Kollias Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level implications for pathogenesis and therapy of autoimmune demyelination J Exp Med 193 4 2001 427 434
31. J.M. Van den Brande, H. Braat, G.R. van den Brink, H.H. Versteeg, C.A. Bauer, I. Hoedemaeker Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease Gastroenterology 124 7 2003 1774 1785
32. A. Lugering, M. Schmidt, N. Lugering, H.G. Pauels, W. Domschke, T. Kucharzik Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway Gastroenterology 121 5 2001 1145 1157
33. J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, W.D. Schwieterman Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N Engl J Med 345 15 2001 1098 1104
34. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associate tuberculosis. AIDS (in press)
35. B.J. Scallon, M.A. Moore, H. Trinh, D.M. Knight, J. Ghrayeb Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions Cytokine 7 3 1995 251 259
36. D.G. Stokes, J.M. Kremer Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis Semin Arthritis Rheum 33 1 2003 1 18